Loading clinical trials...
Loading clinical trials...
Non-Comparative, Multi-Cohort, Single Arm, Open-Label, Phase 2 Study of Nivolumab (BMS-936558) in Classical Hodgkin Lymphoma (cHL) Subjects
The purpose of this study is to evaluate the efficacy and safety of Nivolumab in previously treated (cohorts, A, B \& C) or newly diagnosed (cohort D) classical Hodgkin Lymphoma participants.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Local Institution - 0030
Los Angeles, California, United States
Local Institution - 0009
Los Angeles, California, United States
Local Institution - 0001
Atlanta, Georgia, United States
Local Institution - 0002
Boston, Massachusetts, United States
Local Institution - 0025
Boston, Massachusetts, United States
Local Institution - 0041
Boston, Massachusetts, United States
Local Institution - 0008
Detroit, Michigan, United States
Local Institution - 0003
Rochester, Minnesota, United States
Local Institution - 0047
Hackensack, New Jersey, United States
Local Institution - 0040
Basking Ridge, New York, United States
Start Date
August 12, 2014
Primary Completion Date
August 31, 2017
Completion Date
December 27, 2022
Last Updated
November 28, 2023
294
ACTUAL participants
Nivolumab
DRUG
Doxorubicin
DRUG
Vinblastine
DRUG
Dacarbazine
DRUG
Lead Sponsor
Bristol-Myers Squibb
NCT07209059
NCT02287311
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions